TAZ-induced Cybb contributes to liver tumor formation in non-alcoholic steatohepatitis
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
BACKGROUND & AIMS: Non-alcoholic steatohepatitis (NASH) is a leading cause of hepatocellular carcinoma (HCC), but mechanisms linking NASH to eventual tumor formation remain poorly understood. Herein, we investigate the role of TAZ/WWTR1, which is induced in hepatocytes in NASH, in the progression of NASH to HCC. METHODS: The roles of hepatocyte TAZ and its downstream targets were investigated in diet-induced and genetic models of NASH-HCC using gene-targeting, adeno-associated virus 8 (AAV8)-H1-mediated gene silencing, or AAV8-TBG-mediated gene expression. The biochemical signature of the newly elucidated pathway was probed in liver specimens from humans with NASH-HCC. RESULTS: When hepatocyte-TAZ was silenced in mice with pre-tumor NASH using AAV8-H1-shTaz (short-hairpin Taz), subsequent HCC tumor development was suppressed. In this setting, the tumor-suppressing effect of shTaz was not dependent of TAZ silencing in the tumors themselves and could be dissociated from the NASH-suppressing effects of shTaz. The mechanism linking pre-tumor hepatocyte-TAZ to eventual tumor formation involved TAZ-mediated induction of the NOX2-encoding gene Cybb, which led to NADPH-mediated oxidative DNA damage. As evidence, DNA damage and tumor formation could be suppressed by treatment of pre-tumor NASH mice with AAV8-H1-shCybb; AAV8-TBG-OGG1, encoding the oxidative DNA-repair enzyme 8-oxoguanine glycosylase; or AAV8-TBG-NHEJ1, encoding the dsDNA repair enzyme non-homologous end-joining factor 1. In surrounding non-tumor tissue from human NASH-HCC livers, there were strong correlations between TAZ, NOX2, and oxidative DNA damage. CONCLUSIONS: TAZ in pre-tumor NASH-hepatocytes, via induction of Cybb and NOX2-mediated DNA damage, contributes to subsequent HCC tumor development. These findings illustrate how NASH provides a unique window into the early molecular events that can lead to tumor formation and suggest that NASH therapies targeting TAZ might also prevent NASH-HCC. LAY SUMMARY: Non-alcoholic steatohepatitis (NASH) is emerging as the leading cause of a type of liver cancer called hepatocellular carcinoma (HCC), but molecular events in pre-tumor NASH hepatocytes leading to HCC remain largely unknown. Our study shows that a protein called TAZ in pre-tumor NASH-hepatocytes promotes damage to the DNA of hepatocytes and thereby contributes to eventual HCC. This study reveals a very early event in HCC that is induced in pre-tumor NASH, and the findings suggest that NASH therapies targeting TAZ might also prevent NASH-HCC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Obesity-induced gut microbial metabolite promotes liver cancer through senescence secretome
Yoshimoto, S., Loo, T. M., Atarashi, K., Kanda, H., Sato, S., Oyadomari, S., Iwakura, Y., Oshima, K., Morita, H., Hattori, M., et al. (2013) · Nature · doi:10.1038/nature12347 · Cited by 2,219
Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention
Huang, D. Q., El-Serag, H. B., & Loomba, R. (2021) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-020-00381-6 · Cited by 1,855
From NASH to HCC: current concepts and future challenges
Anstee, Q. M., Reeves, H. L., Kotsiliti, E., Govaere, O., & Heikenwalder, M. (2019) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-019-0145-7 · Cited by 1,392
Michelotti, G. A., Machado, M. V., & Diehl, A. M. (2013) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2013.183 · Cited by 974
The central role of DNA damage in the ageing process
Schumacher, B., Pothof, J., Vijg, J., & Hoeijmakers, J. H. J. (2021) · Nature · doi:10.1038/s41586-021-03307-7 · Cited by 907
Hippo pathway effector Yap promotes cardiac regeneration
Xin, M., Kim, Y., Sutherland, L. B., Murakami, M., Qi, X., McAnally, J., Porrello, E. R., Mahmoud, A. I., Tan, W., Shelton, J. M., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1313192110 · Cited by 895
Mittal, S., El-Serag, H. B., Sada, Y. H., Kanwal, F., Duan, Z., Temple, S., May, S. B., Kramer, J. R., Richardson, P. A., & Davila, J. A. (2016) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2015.07.019 · Cited by 648
Hepatocyte TAZ/WWTR1 Promotes Inflammation and Fibrosis in Nonalcoholic Steatohepatitis
Wang, X., Zheng, Z., Caviglia, J. M., Corey, K. E., Herfel, T. M., Cai, B., Masia, R., Chung, R. T., Lefkowitch, J. H., Schwabe, R. F., et al. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2016.09.016 · Cited by 413
Self-citationHepatocyte Notch activation induces liver fibrosis in nonalcoholic steatohepatitis
Zhu, C., Kim, K., Wang, X., Bartolome, A., Salomao, M., Dongiovanni, P., Meroni, M., Graham, M. J., Yates, K. P., Diehl, A. M., et al. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aat0344 · Cited by 250
Self-citationPerumpail, R. B., Wong, R. J., Ahmed, A., & Harrison, S. A. (2015) · Digestive Diseases and Sciences · doi:10.1007/s10620-015-3821-7 · Cited by 111
Research works printed but not linked: 22
- Loomba, 2013, The global NAFLD epidemic, Nat Rev Gastroenterol Hepatol, 10, 686, 10.1038/nrgastro.2013.171 · DOI · Paper page
- Corey, 2014, Obesity and liver disease: the epidemic of the twenty-first century, Clin Liver Dis, 18, 1, 10.1016/j.cld.2013.09.019 · DOI
- Paradis, 2009, Hepatocellular carcinomas in patients with metabolic syndrome often develop without significant liver fibrosis: a pathological analysis, Hepatology, 49, 851, 10.1002/hep.22734 · DOI · Paper page
- Linhart, 2015, The generation of carcinogenic etheno-DNA adducts in the liver of patients with nonalcoholic fatty liver disease, Hepatobiliary Surg Nutr, 4, 117
- Boege, 2017, A dual role of caspase-8 in triggering and sensing proliferation-associated DNA damage, a key determinant of liver cancer development, Cancer Cell, 32, 342, 10.1016/j.ccell.2017.08.010 · DOI · Paper page
- Kakehashi, 2020, Accumulation of 8-hydroxydeoxyguanosine, L-arginine and glucose metabolites by liver tumor cells are the important characteristic features of metabolic syndrome and non-alcoholic steatohepatitis-associated hepatocarcinogenesis, Int J Mol Sci, 21, 7746, 10.3390/ijms21207746 · DOI
- Yang, 2021, Hepatocyte-specific TAZ deletion downregulates p62/Sqstm1 expression in nonalcoholic steatohepatitis, Biochem Biophys Res Commun, 535, 60, 10.1016/j.bbrc.2020.12.038 · DOI
- Khajehahmadi, 2019, Downregulation of hedgehog ligands in human simple steatosis may protect against nonalcoholic steatohepatitis: is TAZ a crucial regulator?, IUBMB Life, 71, 1382, 10.1002/iub.2068 · DOI · Paper page
- Wang, 2020, Cholesterol stabilizes TAZ in hepatocytes to promote experimental non-alcoholic steatohepatitis, Cell Metab, 31, 969, 10.1016/j.cmet.2020.03.010 · DOI · Paper page
- Pinyol, 2021, Molecular characterisation of hepatocellular carcinoma in patients with non-alcoholic steatohepatitis, J Hepatol, 75, 865, 10.1016/j.jhep.2021.04.049 · DOI · Paper page
- Chuma, 2008, 8-Hydroxy-2'-deoxy-guanosine is a risk factor for development of hepatocellular carcinoma in patients with chronic hepatitis C virus infection, J Gastroenterol Hepatol, 23, 1431, 10.1111/j.1440-1746.2008.05502.x · DOI
- Hagenbeek, 2018, The Hippo pathway effector TAZ induces TEAD-dependent liver inflammation and tumors, Sci Signal, 11, 10.1126/scisignal.aaj1757 · DOI · Paper page
- Hayashi, 2015, An imbalance in TAZ and YAP expression in hepatocellular carcinoma confers cancer stem cell-like behaviors contributing to disease progression, Cancer Res, 75, 4985, 10.1158/0008-5472.CAN-15-0291 · DOI · Paper page
- Wang, 2021, Distinct and overlapping roles of hippo effectors YAP and TAZ during human and mouse hepatocarcinogenesis, Cell Mol Gastroenterol Hepatol, 11, 1095, 10.1016/j.jcmgh.2020.11.008 · DOI
- Wang, 2019, A therapeutic silencing RNA targeting hepatocyte TAZ prevents and reverses fibrosis in nonalcoholic steatohepatitis in mice, Hepatol Commun, 3, 1221, 10.1002/hep4.1405 · DOI · Paper page
- Zhu, 2021, Notch activity characterizes a common hepatocellular carcinoma subtype with unique molecular and clinicopathologic features, J Hepatol, 74, 613, 10.1016/j.jhep.2020.09.032 · DOI
- Moon, 2019, High risk of hepatocellular carcinoma development in fibrotic liver: role of the Hippo-YAP/TAZ signaling pathway, Int J Mol Sci, 20, 581, 10.3390/ijms20030581 · DOI
- Zhang, 2019, Role of the transcriptional coactivators YAP/TAZ in liver cancer, Curr Opin Cell Biol, 61, 64, 10.1016/j.ceb.2019.07.006 · DOI
- Peiseler, 2021, Inflammatory mechanisms underlying nonalcoholic steatohepatitis and the transition to hepatocellular carcinoma, Cancers (Basel), 13, 10.3390/cancers13040730 · DOI · Paper page
- Nishimura, 2001, Mammalian Ogg1/Mmh gene plays a major role in repair of the 8-hydroxyguanine lesion in DNA, Prog Nucleic Acid Res Mol Biol, 68, 107, 10.1016/S0079-6603(01)68093-0 · DOI
- Okada, 2006, The role of nicotinamide adenine dinucleotide phosphate oxidase-derived reactive oxygen species in the acquisition of metastatic ability of tumor cells, Am J Pathol, 169, 294, 10.2353/ajpath.2006.060073 · DOI
- Choi, 2014, Oxidative stress and hepatic Nox proteins in chronic hepatitis C and hepatocellular carcinoma, Free Radic Biol Med, 72, 267, 10.1016/j.freeradbiomed.2014.04.020 · DOI
Cited by
Diabetes mellitus—Progress and opportunities in the evolving epidemic
Abel, E. D., Gloyn, A. L., Evans-Molina, C., Joseph, J. J., Misra, S., Pajvani, U. B., Simcox, J., Susztak, K., & Drucker, D. J. (2024) · Cell · doi:10.1016/j.cell.2024.06.029 · Cited by 292
Self-citationLoss of liver function in chronic liver disease: An identity crisis
Berasain, C., Arechederra, M., Argemí, J., Fernández-Barrena, M. G., & Avila, M. A. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2022.09.001 · Cited by 99
miR-33 deletion in hepatocytes attenuates MASLD-MASH-HCC progression
Fernández-Tussy, P., Cardelo, M. P., Zhang, H., Sun, J., Price, N. L., Boutagy, N. E., Goedeke, L., Cadena-Sandoval, M., Xirouchaki, C. E., Brown, W., et al. (2024) · JCI Insight · doi:10.1172/jci.insight.168476 · Cited by 21
“…of miR-33 target genes, such as carnitine palmitoyltrans-ferase 1A (CPT1 α ), PPARG coactivator 1 alpha (PGC1 α ), and AMPK α . miR-33 regulation of AMPK α contributes to the regulation of a subset of downstream targets and pathways, which have been recently implicated in MASH progression (44–49).”
BackgroundInfluentialWang, X., Moore, M. P., Shi, H., Miyata, Y., Donnelly, S. K., Radiloff, D. R., & Tabas, I. (2023) · Molecular Therapy Methods & Clinical Development · doi:10.1016/j.omtm.2023.101165 · Cited by 21
Self-citation
Metadata
- Authors
- Wang, X., Zeldin, S., Shi, H., Zhu, C., Saito, Y., Corey, K. E., Osganian, S. A., Remotti, H. E., Verna, E. C., Pajvani, U. B., Schwabe, R. F., & Tabas, I.
- Venue
- Journal of Hepatology
- Publisher
- Elsevier BV
- Published
- 2022-04
- Volume
- 76
- Issue
- 4
- Pages
- 910-920
- ISSN
- 0168-8278 (ISSN-L)
- OpenAlex
- W4200005504
- Cited by
- 42
- References
- 10
- FWCI
- 3.26
- Type
- journal article
- Language
- en
- Open access
- hybrid
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- Funders
- National Institutes of Health (DK103818, R01DK116620, DK119767, R01CA190844, R01CA228483)
- National Cancer Institute (30 CA013696)
- American Liver Foundation
- University of Minnesota (HHSN276201200017C)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: TAZ-induced Cybb contributes to liver tumor formation in non-alcoholic steatohepatitis. https://app.cochat.ai/papers/10.1016/j.jhep.2021.11.031
- The paper
- Wang, X., Zeldin, S., Shi, H., Zhu, C., Saito, Y., Corey, K. E., Osganian, S. A., Remotti, H. E., Verna, E. C., Pajvani, U. B., Schwabe, R. F., & Tabas, I. (2022). TAZ-induced Cybb contributes to liver tumor formation in non-alcoholic steatohepatitis. Journal of Hepatology. https://doi.org/10.1016/j.jhep.2021.11.031
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.